Priorities for the primary prevention of breast cancer

CA Cancer Journal for Clinicians

Volumn 64, Issue 3, 2014, Pages 186-194

  Colditz, Graham A ^a   Bohlke, Kari ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; chemoprevention; epidemiology; primary prevention; timing

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VASCULOTROPIN RECEPTOR;

ALCOHOL CONSUMPTION; BEHAVIOR CHANGE; BODY WEIGHT; BREAST CANCER; BREAST FEEDING; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; FEMALE; HEALTH CARE UTILIZATION; HEALTH PROMOTION; HIGH RISK POPULATION; HUMAN; MEDICAL RESEARCH; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

BREAST CANCER; CHEMOPREVENTION; EPIDEMIOLOGY; PRIMARY PREVENTION; TIMING;

ALCOHOLIC BEVERAGES; BODY WEIGHT; BREAST NEOPLASMS; CHEMOPREVENTION; EXERCISE; FEMALE; HUMANS; PRIMARY PREVENTION;

EID: 84901394164     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21225     Document Type: Review

References (94)

1. American Cancer Society. Cancer Facts a Figures 2013. Atlanta, GA: American Cancer Society, Inc.; 2013.
2. National Institutes of Health (NIH). Report of the Interagency Breast Cancer and Environmental Research Coordinating Committee. Breast Cancer and the Environment: Prioritizing Prevention. Bethesda, MD: NIH; 2013.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW,. Cancer genome landscapes. Science. 2013; 339: 1546-1558.
4. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer/World Health Organization; 2012. globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed January 26, 2014.
5. American Cancer Society. Global Cancer Facts & Figures. 2nd ed. Atlanta, GA: American Cancer Society, Inc.; 2011.
6. Colditz GA, Sellers TA, Trapido E,. Epidemiology-identifying the causes and preventability of cancer? Nat Rev Cancer. 2006; 6: 75-83.
7. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993; 85: 1819-1827.
8. Shin HR, Joubert C, Boniol M, et al. Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control. 2010; 21: 1777-1785.
9. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS,. Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat. 2013; 45: 15-21.
10. Cho GJ, Park HT, Shin JH, et al. Age at menarche in a Korean population: secular trends and influencing factors. Eur J Pediatr. 2010; 169: 89-94.
11. Lim JW,. The changing trends in live birth statistics in Korea, 1970 to 2010. Korean J Pediatr. 2011; 54: 429-435.
12. Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences [serial online]. Popul Health Metr. 2012; 10: 22.
13. Land CE, Tokunaga M, Koyama K, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res. 2003; 160: 707-717.
14. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans. Alcohol Consumption and Ethyl Carbamate. Lyon, France: International Agency for Research on Cancer (distributed by WHO Press); 2010.
15. International Agency for Research on Cancer. Weight Control and Physical Activity. Vol 6. Lyon, France: International Agency for Research on Cancer; 2002.
16. International Agency for Research on Cancer. Monograph on the Valuation of Carcinogenic Risk to Humans: Combined Estrogen/Progestogen Contraceptives and Combined Estrogen/Progesterone Menopausal Therapy. Vol 91. Lyon, France: IARC Press; 2008.
17. Liu Y, Tamimi RM, Berkey CS, et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease. Pediatrics. 2012; 129: e1192-e1198.
18. Liu Y, Colditz GA, Rosner B, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 2013; 105: 1571-1578.
19. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC,. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011; 306: 1884-1890.
20. Smith-Warner SA, Spiegelman D, Yaun S-S, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998; 279: 535-540.
21. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE,. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006; 296: 193-201.
22. Bernstein L, Patel AV, Ursin G, et al. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst. 2005; 97: 1671-1679.
23. Korde LA, Wu AH, Fears T, et al. Childhood soy intake and breast cancer risk in Asian American women. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1050-1059.
24. Jung S, Spiegelman D, Baglietto L, et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst. 2013; 105: 219-236.
25. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet. 2002; 360: 187-195.
26. Rebbeck TR, Kauff ND, Domchek SM,. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101: 80-87.
27. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998; 90: 1371-1388.
28. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31: 2942-2962.
29. London SJ, Connolly JL, Schnitt SJ, Colditz GA,. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992; 267: 941-944.
30. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005; 97: 1652-1662.
31. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004; 96: 1751-1761.
32. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011; 364: 2381-2391.
33. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007; 99: 272-282.
34. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M,. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007; 99: 283-290.
35. Colditz GA, Rosner B,. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000; 152: 950-964.
36. American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta, GA: American Cancer Society, Inc.; 2013.
37. Dart H, Wolin KY, Colditz GA,. Commentary: eight ways to prevent cancer: a framework for effective prevention messages for the public. Cancer Causes Control. 2012; 23: 601-608.
38. Flegal KM, Carroll MD, Kit BK, Ogden CL,. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307: 491-497.
39. Carlson SA, Fulton JE, Schoenborn CA, Loustalot F,. Trend and prevalence estimates based on the 2008 Physical Activity Guidelines for Americans. Am J Prev Med. 2010; 39: 305-313.
40. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012; 118: 2338-2366.
41. Baer HJ, Tworoger SS, Hankinson SE, Willett WC,. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol. 2010; 171: 1183-1194.
42. Key T, Appleby P, Barnes I, Reeves G,. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94: 606-616.
43. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003; 95: 1218-1226.
44. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M,. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569-578.
45. Fabian CJ, Kimler BF, Donnelly JE, et al. Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10% weight loss in postmenopausal women. Breast Cancer Res Treat. 2013; 142: 119-132.
46. Kushi LH, Doyle C, McCullough M, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012; 62: 30-67.
47. Wu Y, Zhang D, Kang S,. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2013; 137: 869-882.
48. Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012; 380: 219-229.
49. Hildebrand JS, Gapstur SM, Campbell PT, Gaudet MM, Patel AV,. Recreational physical activity and leisure-time sitting in relation to postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1906-1912.
50. Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC,. Physical activity and risk of breast cancer among postmenopausal women. Arch Intern Med. 2010; 170: 1758-1764.
51. Lynch BM, Neilson HK, Friedenreich CM,. Physical activity and breast cancer prevention. Recent Results Cancer Res. 2011; 186: 13-42.
52. Maruti SS, Willett WC, Feskanich D, Rosner B, Colditz GA,. A prospective study of age-specific physical activity and premenopausal breast cancer. J Natl Cancer Inst. 2008; 100: 728-737.
53. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK,. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst. 1994; 86: 1403-1408.
54. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002; 87: 1234-1245.
55. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA,. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis [serial online]. BMJ. 2011; 342: d671.
56. Thun M, Peto R, Lopez A, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med. 1997; 337: 1705-1714.
57. Thomson CA, McCullough ML, Wertheim BC, et al. Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the Women's Health Initiative. Cancer Prev Res (Phila). 2014; 7: 42-53.
58. Moyer VA,. Medications for risk reduction of primary breast cancer in women: US Preventive Services Task Force recommendation statement [published online ahead of print September 24, 2013]. Ann Intern Med. 2013.
59. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol. 2011; 29: 2327-2333.
60. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010; 3: 696-706.
61. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999; 91: 1829-1846.
62. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH,. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003; 95: 526-532.
63. Chen WY, Rosner B, Colditz GA,. Moving forward with breast cancer prevention. Cancer. 2007; 109: 2387-2391.
64. Waters EA, McNeel TS, Stevens WM, Freedman AN,. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012; 134: 875-880.
65. Kaplan CP, Kim SE, Wong ST, Sawaya GF, Walsh JM, Perez-Stable EJ,. Willingness to use tamoxifen to prevent breast cancer among diverse women. Breast Cancer Res Treat. 2012; 133: 357-366.
66. Waters EA, Weinstein ND, Colditz GA, Emmons K,. Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol. 2009; 28: 201-209.
67. Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich SE,. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med. 2005; 41: 7-15.
68. Taylor R, Taguchi K,. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005; 3: 242-247.
69. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.
70. Colditz GA, Frazier AL,. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995; 4: 567-571.
71. Institute of Medicine. Breast Cancer and the Environment: A Life Course Approach. Washington, DC: National Academies Press; 2012.
72. Berkey CS, Frazier AL, Gardner JD, Colditz GA,. Adolescence and breast carcinoma risk. Cancer. 1999; 85: 2400-2409.
73. Matthews CE, Shu XO, Jin F, et al. Lifetime physical activity and breast cancer risk in the Shanghai Breast Cancer Study. Br J Cancer. 2001; 84: 994-1001.
74. Lee SA, Shu XO, Li H, et al. Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr. 2009; 89: 1920-1926.
75. Berkey CS, Rockett HR, Field AE, Gillman MW, Colditz GA,. Sugar-added beverages and adolescent weight change. Obes Res. 2004; 12: 778-788.
76. Su X, Tamimi RM, Collins LC, et al. Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease. Cancer Causes Control. 2010; 21: 1033-1046.
77. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
78. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
79. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
80. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109: 123-139.
81. Tamimi RM, Colditz GA, Hazra A, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012; 131: 159-167.
82. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 103: 250-263.
83. Ambrosone CB, Zirpoli G, Ruszczyk M, et al. Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control. 2014; 25: 259-265.
84. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE,. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 2013; 137: 579-587.
85. Boyle P,. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23 (suppl 6): vi7-vi12.
86. Eliassen AH, Hendrickson SJ, Brinton LA, et al. Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst. 2012; 104: 1905-1916.
87. Esserman LJ, Thompson IM, Jr, Reid B,. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013; 310: 797-798.
88. Makin JK, Warne CD, Dobbinson SJ, Wakefield MA, Hill DJ,. Population and age-group trends in weekend sun protection and sunburn over two decades of the SunSmart Programme in Melbourne, Australia. Br J Dermatol. 2013; 168: 154-161.
89. Elley CR, Kerse N, Arroll B, Robinson E,. Effectiveness of counselling patients on physical activity in general practice: cluster randomised controlled trial [serial online]. BMJ. 2003; 326: 793.
90. Johnston LD, Bachman JG, O'Malley PM, Schulenberg JE,. Monitoring the Future: A Continuing Study of American Youth (12th-Grade Survey), 2009. wonder.cdc.gov/data2010. Accessed January 30, 2014.
91. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2011. MMWR Surveill Summ. 2012; 61: 1-162.
92. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2005. MMWR Surveill Summ. 2006; 55: 1-108.
93. Whitlock EP, Orleans CT, Pender N, Allan J,. Evaluating primary care behavioral counseling interventions: an evidence-based approach. Am J Prev Med. 2002; 22: 267-284.
94. Atwood K, Colditz GA, Kawachi I,. From public health science to prevention policy: placing science in its social and political contexts. Am J Public Health. 1997; 87: 1603-1606.